BACKGROUND AND AIMS: Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglitazone are equally plausible options to improve glycemic control. However, these drugs have profound differences in their mechanism of action, side effects, and impact on cardiovascular risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking. The TOSCA.IT study was designed to explore the effects of adding pioglitazone or a sulfonylurea on cardiovascular events in type 2 diabetic patients inadequately controlled withmetformin. METHODS: Multicentre, randomized, open label, parallel group trial of 48 month duration. Type 2 diabetic subjects, 50-75 years, BMI 20-45 Kg/m(2), on secondary failure tometformin monotherapy will be randomized to add-on a sulfonylurea or pioglitazone. The primary efficacy outcome is a composite endpoint of all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, and unplanned coronary revascularization. Principal secondary outcome is a composite ischemic endpoint of sudden death, fatal and non-fatal myocardial infarction and stroke, endovascular or surgical intervention on the coronary, leg or carotid arteries, major amputations. Side effects, quality of life and economic costs will also be evaluated. Efficacy, safety, tolerability, and study conduct will be monitored by an independent Data Safety Monitoring Board. End points will be adjudicated by an independent external committee. CONCLUSIONS:TOSCA.IT is the first on-going study investigating the head-to-head comparison of adding a sulfonylurea or pioglitazone to existing metformin treatment in terms of hard cardiovascular outcomes. REGISTRATION: Clinicaltrials.gov ID NCT00700856.
RCT Entities:
BACKGROUND AND AIMS: Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglitazone are equally plausible options to improve glycemic control. However, these drugs have profound differences in their mechanism of action, side effects, and impact on cardiovascular risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking. The TOSCA.IT study was designed to explore the effects of adding pioglitazone or a sulfonylurea on cardiovascular events in type 2 diabeticpatients inadequately controlled with metformin. METHODS: Multicentre, randomized, open label, parallel group trial of 48 month duration. Type 2 diabetic subjects, 50-75 years, BMI 20-45 Kg/m(2), on secondary failure to metformin monotherapy will be randomized to add-on a sulfonylurea or pioglitazone. The primary efficacy outcome is a composite endpoint of all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, and unplanned coronary revascularization. Principal secondary outcome is a composite ischemic endpoint of sudden death, fatal and non-fatal myocardial infarction and stroke, endovascular or surgical intervention on the coronary, leg or carotid arteries, major amputations. Side effects, quality of life and economic costs will also be evaluated. Efficacy, safety, tolerability, and study conduct will be monitored by an independent Data Safety Monitoring Board. End points will be adjudicated by an independent external committee. CONCLUSIONS: TOSCA.IT is the first on-going study investigating the head-to-head comparison of adding a sulfonylurea or pioglitazone to existing metformin treatment in terms of hard cardiovascular outcomes. REGISTRATION: Clinicaltrials.gov ID NCT00700856.
Authors: M Vitale; M Masulli; A A Rivellese; E Bonora; F Cappellini; A Nicolucci; S Squatrito; D Antenucci; A Barrea; C Bianchi; F Bianchini; L Fontana; P Fornengo; F Giorgino; A Gnasso; E Mannucci; A Mazzotti; R Nappo; A P Palena; P Pata; G Perriello; S Potenziani; R Radin; L Ricci; F Romeo; C Santini; M Scarponi; R Serra; A Timi; A A Turco; M Vedovato; D Zavaroni; S Grioni; G Riccardi; O Vaccaro Journal: Eur J Nutr Date: 2016-12-21 Impact factor: 5.614
Authors: Charles E Leonard; Sean Hennessy; Xu Han; David S Siscovick; James H Flory; Rajat Deo Journal: Trends Endocrinol Metab Date: 2017-05-22 Impact factor: 12.015
Authors: Donna E Seabloom; Arthur R Galbraith; Anna M Haynes; Jennifer D Antonides; Beverly R Wuertz; Wendy A Miller; Kimberly A Miller; Vernon E Steele; Mark Steven Miller; Margie L Clapper; M Gerard O'Sullivan; Frank G Ondrey Journal: Cancer Prev Res (Phila) Date: 2017-01-04
Authors: M Vitale; M Masulli; A A Rivellese; A C Babini; M Boemi; E Bonora; R Buzzetti; O Ciano; M Cignarelli; M Cigolini; G Clemente; G Citro; L Corsi; E Dall'Aglio; S Del Prato; G Di Cianni; M A Dolci; C Giordano; R Iannarelli; C Iovine; A Lapolla; D Lauro; S Leotta; C Mazzucchelli; V Montani; G Perriello; G Romano; F Romeo; L Santarelli; R Schiano di Cola; S Squatrito; L Tonutti; R Trevisan; A A Turco; C Zamboni; G Riccardi; O Vaccaro Journal: Eur J Nutr Date: 2015-08-25 Impact factor: 5.614